Evidence map›Paper›PMID 30467717›Full record

ReviewCurrent genetics2019

DDR Inc., one business, two associates.

María Moriel-Carretero, Philippe Pasero, Benjamin Pardo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Versatility of the Mec1Current genetics · 2019
    Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

María Moriel-CarreteroEquipe Labellisée Ligue contre le Cancer, Institut de Génétique Humaine, CNRS and Université de Montpellier, Montpellier, France.ORCID http://orcid.org/0000-0002-6770-3486
Philippe PaseroEquipe Labellisée Ligue contre le Cancer, Institut de Génétique Humaine, CNRS and Université de Montpellier, Montpellier, France.ORCID http://orcid.org/0000-0001-5891-0822
Benjamin PardoEquipe Labellisée Ligue contre le Cancer, Institut de Génétique Humaine, CNRS and Université de Montpellier, Montpellier, France. benjamin.pardo@igh.cnrs.fr.ORCID http://orcid.org/0000-0002-4760-1263
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eukaryotic cells activate cell cycle checkpoints in response to DNA damage. In Saccharomyces cerevisiae, the DNA damage response is achieved by the activation of the sensor kinases Mec1 and Tel1 and transmitted to the effector kinase Rad53. Rad9 and Mrc1 are thought to differentially mediate the activation of Rad53 depending on the cell cycle phase. Rad9 can respond to DNA lesions throughout the cell cycle, whereas Mrc1 responds to replication impediments in S phase. It was not clear if Rad9 and Mrc1 were triggering the same response to DNA damage occurring in S phase. By carefully studying the kinetics of activation of Rad53 by different types of replication stresses, we recently showed that Rad9 and Mrc1 cooperate in time and space to trigger a unique response to DNA damage in S phase. This primarily includes the control of both DNA replication initiation and elongation. After showing that Rad9 plays a preponderant role during S phase, the data presented here provocatively suggest that Mrc1 could also mediate the activation of Rad53 outside of S phase.

Indexed as

Adaptation, BiologicalDNA DamageBiomarkersDNA ReplicationGene Expression Regulation, FungalSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSignal TransductionS Phase Cell Cycle CheckpointsBiomarkersSaccharomyces cerevisiae ProteinsDNA replicationMediatorsMrc1Rad9Replication stressS-phase checkpoint

Identifiers

PMID30467717
OpenAlexW2900543379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.